Skip to main content

Table 1 Comparison of clinicopathologic features

From: Influence of cirrhosis on long-term prognosis after surgery in patients with combined hepatocellular-cholangiocarcinoma

Variables

Cirrhosis

n = 91

Non- cirrhosis

n = 53

P-value

Sex (male/female), n

89/2

46/7

0.274

Age (years; mean ± SD)

53.2 ± 9.2

52.1 ± 8.1

0.463

Overweight (BMI 25.0-29.99 kg/m2), n (%)

15 (16.5)

10 (18.9)

0.716

Obesity (BMI ≥ 30 kg/m2), n (%)

3 (3.3)

2 (3.8)

0.880

Hypertension, n (%)

12 (13.2)

6 (11.3)

0.744

Diabetes mellitus, n (%)

10 (11.0)

4 (7.5)

0.501

Hepatitis B surface antigen, n (%)

79 (63.8)

22 (37.2)

<0.001

Alcohol use, n (%)

24 (26.4)

5 (9.4)

0.015

Total bilirubin (μmol/L; mean ± SD)

17.8 ± 8.8

15.4 ± 4.1

0.090

Albumin (g/L; mean ± SD)

40.5 ± 5.3

41.2 ± 4.6

0.417

Aspartate aminotransferase (IU/L; mean ± SD)

51.2 ± 35.3

39.6 ± 22.3

0.021

Alanine aminotransferase (IU/L; mean ± SD)

54.5 ± 50.6

41.8 ± 36.7

0.043

Child-Pugh (A/B), n

85/6

53/0

0.056

Tumor diameter (cm; mean ± SD)

4.9 ± 2.5

6.7 ± 2.8

<0.001

Tumor number (St/Mt), n

82/9

46/7

0.541

Encapsulation, n (%)

34 (37.4)

15 (28.3)

0.268

Vascular invasion, n (%)

41 (45.1)

27 (50.9)

0.495

Bile duct invasion, n (%)

17 (18.7)

11(20.8)

0.762

Lymph node involvement, n (%)

12 (13.2)

8 (15.1)

0.750

Alpha-fetoprotein ≥ 20 ng/mL, n (%)

56 (61.5)

22 (41.5)

0.020

Carbohydrate antigen 19–9 ≥ 37 U/mL, n (%)

31 (34.1)

21 (39.6)

0.503

Carcinoembryogenic antigen ≥ 5 ng/mL, n (%)

7 (7.7)

3 (5.7)

0.644

  1. BMI body mass index; St single tumor; Mt multiple tumors